S-1/A: Aptevo Therapeutics Seeks Up to $4.6 Million in Public Offering to Advance Cancer Immunotherapy Pipeline

Aptevo Therapeutics is launching a public offering of common stock and warrants to raise capital for clinical programs and general corporate purposes.

Summary

• Aptevo Therapeutics Inc. is offering up to 922,509 shares of common stock along with common warrants to purchase up to 1,845,018 shares.
• The offering also includes pre-funded warrants for certain purchasers who would exceed ownership limits, exercisable for one share of common stock at $0.0001 per share.
• Each share of common stock or pre-funded warrant is offered with two common warrants, each exercisable for one share of common stock at an exercise price of $5.42 per share, expiring five years from issuance.
• The company intends to use the net proceeds of approximately $4.6 million for working capital, clinical programs, and general corporate purposes.
• Roth Capital Partners, LLC is acting as the exclusive placement agent for the offering, which will terminate no later than April 20, 2024.
• The offering does not have a minimum number of securities or minimum aggregate amount of proceeds that is a condition for this offering to close.
• The company's common stock is listed on the Nasdaq Capital Market under the symbol APVO.
• The company completed a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-44 on March 5, 2024.

Sentiment

Score: 6

Explanation: The document is neutral in tone, presenting facts about the offering. The company is raising capital, which can be seen as a positive, but there are also risks and potential dilution for investors.

Positives

• The offering provides Aptevo with additional capital to advance its clinical programs and support general corporate purposes.
• The inclusion of pre-funded warrants allows certain investors to participate without exceeding ownership limitations.
• The warrants provide potential future capital if exercised.
• The company has flexibility in allocating the net proceeds of the offering.

Negatives

• There is no guarantee that the company will sell all of the offered securities.
• The offering may result in immediate and substantial dilution for existing stockholders.
• There is no established public trading market for the pre-funded warrants or common warrants.
• The actual offering amount, placement agent fees, and proceeds to the company are not presently determinable and may be substantially less than the total maximum offering amounts set forth above.

Risks

• The company has broad discretion in the use of the net proceeds from this offering and may not use them effectively.
• Investors will experience immediate and substantial dilution in the net tangible book value per share of the common stock they purchase.
• There is no public market for the common warrants or pre-funded warrants being offered.
• The placement agent has agreed to use its reasonable best efforts to solicit offers to purchase the securities in this offering.
• The offering may cause the trading price of the company's common stock to decrease.

Future Outlook

Aptevo intends to use the net proceeds from this offering for working capital to fund its clinical programs and general corporate purposes, including the further development of its product candidates.

Industry Context

Bispecific therapeutics are increasingly recognized as potent anti-cancer agents, with nine new bispecific agents approved by the FDA in the last three years and a total of 125 bispecific drug candidates currently in development.

Comparison to Industry Standards

• The document does not contain specific comparisons to industry standards.
• The document does not contain specific comparisons to comparable companies.
• The document does not contain specific comparisons to projects.
• The document does not contain specific comparisons to results.

Stakeholder Impact

• Shareholders may experience dilution.
• The company's ability to fund its operations and develop its product candidates may be enhanced.
• The offering could impact the market price of the company's common stock.

Next Steps

• The company plans to close the offering by April 20, 2024.
• The company will use the proceeds for clinical development and general corporate purposes.

Key Dates

Keywords

public offering, common stock, warrants, pre-funded warrants, Aptevo Therapeutics, clinical programs, capital raise, immunotherapy, Roth Capital Partners, biotechnology